Reference |
---|
Zhang Y, Velez-Delgado A, Mathew E, Li D, Mendez F, Flannagan K, et al. Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer. Gut. 2017;66:124-136 pubmed publisher
|
Klein J, Moses K, Zelinskyy G, Sody S, Buer J, Lang S, et al. Combined toll-like receptor 3/7/9 deficiency on host cells results in T-cell-dependent control of tumour growth.. Nat Commun. 2017;8:14600 pubmed publisher
|
Woan K, Lienlaf M, Perez-Villaroel P, Lee C, Cheng F, Knox T, et al. Targeting histone deacetylase 6 mediates a dual anti-melanoma effect: Enhanced antitumor immunity and impaired cell proliferation. Mol Oncol. 2015;9:1447-57 pubmed publisher
|
Coffelt S, Kersten K, Doornebal C, Weiden J, Vrijland K, Hau C, et al. IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis. Nature. 2015;522:345-8 pubmed publisher
|
Yamada D, Elsaesser H, Lux A, Timmerman J, Morrison S, de la Torre J, et al. Suppression of Fcγ-receptor-mediated antibody effector function during persistent viral infection. Immunity. 2015;42:379-90 pubmed publisher
|
Vanpouille-Box C, Diamond J, Pilones K, Zavadil J, Babb J, Formenti S, et al. TGFβ Is a Master Regulator of Radiation Therapy-Induced Antitumor Immunity. Cancer Res. 2015;75:2232-42 pubmed publisher
|
Twyman-Saint Victor C, Rech A, Maity A, Rengan R, Pauken K, Stelekati E, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015;520:373-7 pubmed publisher
|
Voron T, Colussi O, Marcheteau E, Pernot S, Nizard M, Pointet A, et al. VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors. J Exp Med. 2015;212:139-48 pubmed publisher
|
Van der Jeught K, Joe P, Bialkowski L, Heirman C, Daszkiewicz L, Liechtenstein T, et al. Intratumoral administration of mRNA encoding a fusokine consisting of IFN-β and the ectodomain of the TGF-β receptor II potentiates antitumor immunity. Oncotarget. 2014;5:10100-13 pubmed
|
Michaud M, Xie X, Bravo-San Pedro J, Zitvogel L, White E, Kroemer G. An autophagy-dependent anticancer immune response determines the efficacy of melanoma chemotherapy. Oncoimmunology. 2014;3:e944047 pubmed
|
Deng L, Liang H, Burnette B, Beckett M, Darga T, Weichselbaum R, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest. 2014;124:687-95 pubmed publisher
|
Deberge M, Ely K, Enelow R. Soluble, but not transmembrane, TNF-α is required during influenza infection to limit the magnitude of immune responses and the extent of immunopathology. J Immunol. 2014;192:5839-51 pubmed publisher
|
Zhang Y, Yan W, Mathew E, Bednar F, Wan S, Collins M, et al. CD4+ T lymphocyte ablation prevents pancreatic carcinogenesis in mice. Cancer Immunol Res. 2014;2:423-35 pubmed publisher
|
Vegran F, Berger H, Boidot R, Mignot G, Bruchard M, Dosset M, et al. The transcription factor IRF1 dictates the IL-21-dependent anticancer functions of TH9 cells. Nat Immunol. 2014;15:758-66 pubmed publisher
|
Pasche N, Wulhfard S, Pretto F, Carugati E, Neri D. The antibody-based delivery of interleukin-12 to the tumor neovasculature eradicates murine models of cancer in combination with paclitaxel. Clin Cancer Res. 2012;18:4092-103 pubmed publisher
|
Quezada S, Simpson T, Peggs K, Merghoub T, Vider J, Fan X, et al. Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med. 2010;207:637-50 pubmed publisher
|
Sandoval F, Terme M, Nizard M, Badoual C, Bureau M, Freyburger L, et al. Mucosal imprinting of vaccine-induced CD8⁺ T cells is crucial to inhibit the growth of mucosal tumors. Sci Transl Med. 2013;5:172ra20 pubmed publisher
|
Kearl T, Jing W, Gershan J, Johnson B. Programmed death receptor-1/programmed death receptor ligand-1 blockade after transient lymphodepletion to treat myeloma. J Immunol. 2013;190:5620-8 pubmed publisher
|